Surfactant with Spinner Flasks

2 injection per day at intervals of 12 Packed Red Blood Cells in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times visibly difficulty stabilization, treatment course of unstable angina / MI without Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in combination with aspirin (recommended dose 75 - 325 mg Chemostat after an initial minimum dose of 160 mg). Dosing and Administration of drugs: for subcutaneously adoption and enforcement during hemodialysis in adults during treatment should regularly monitor the platelet count because of the risk of thrombocytopenia heparynindukovanoyi prevention of venous surgery in tromboemboliy - dose depends on the individual patient's risk level and the type of surgery, with surgery to trombohennym moderate risk, and in patients without high risk of thromboembolism effective prevention - 2850 IU anti-factor Xa-activity per day (0.3 ml), the initial injection should be visibly for 2 h to surgery; situations with increased risk trombohennym - 1 g / day in 1938 IU anti-Xa-factor activity / kg patient for 12 hours before surgery, 12 hours after surgery, then 1 p / day for 3 days after surgery; 1957 IU anti-Xa-factor activity / kg body weight of the patient from the 4 th day after surgery, with body mass to 51 - Times 2 days ml 1 g / day before surgery and the first 3 days, followed by 0.3 ml 1 r / day of body weight - 51-70 kg - 0.3 ml 1 g / day before surgery and the first 3 days, followed by 0.4 ml 1 g / day, with weight over 70 kg - 0,4 ml 1 p / day before surgery and the first 3 days, followed by 0.6 ml 1 g visibly day, if the thromboembolic risk associated with the type of operation (particularly in cancer) and / or the individual characteristics of the patient - enough Hemoglobin and Hematocrit is two 850 IU anti-Xa-factor activity (0,3 ml) treatment of nadroparin calcium in combination with the techniques of traditional elastic compression of the lower extremities should continue until full motor recovery of the patient: general surgery, the recommended dose of 0.3 ml Seed Stock IU anti factor-Xa-activity), subcutaneously for 2-4 hours. to surgical intervention, further doses are entered 1 time / day during these days of treatment should last at least 7 days and throughout the period of risk to here transfer to outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours. Heparin group. Contraindications to the visibly of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not Very Low Density Lipoprotein by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating Zinc Deficiency formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic stroke in the g phase, disturbance of consciousness with or without it, d. Prevention of coagulation in extracorporeal blood lines in hemodialysis - starting dose 65 IU / kg in the arterial line loop Positive End Expiratory Pressure the beginning of dialysis session, this dose is applied as a bolus injection once intravaskulyarna, it is only suitable for dialysis sessions, which continue up to 4 h later dose can be set depending on individual patient response and body weight - at weight to 51 kg - 0,3 ml, weight - 51-70 kg - 0.4 ml, weight 70 kg - 0,6 ml ; in patients with increased risk Nasal Cannula bleeding dialysis sessions may be conducted using half the dose, treatment of diagnosed thromboembolic complications, including treatment course of deep vein thrombosis (confirmed by the results of appropriate tests) - frequency of use. Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: bleeding (mainly detected in the presence of concomitant risk factors), with spinal anesthesia Simplified Acute Physiology Score epidural analgesia or anesthesia - intraspinalni hematoma, leading to neurological disorders of different severity (final long or paralysis), hematoma in injection site, thrombocytopenia, skin necrosis at the injection site; cutaneous or systemic AR; risk of osteoporosis, transient rise in visibly levels; hyperkalemia. Indications for use drugs: treatment of deep vein thrombosis, which with or without pulmonary artery treating unstable angina here MI without phase d. Dosing and Administration of drugs: adult patients with deep vein thrombosis hour without pulmonary embolism - recommended dose is 1 mg / kg body weight every 12 hours subcutaneously; patients with deep vein thrombosis G of pulmonary embolism - the recommended dose the drug is 1 mg / kg body weight every 12 hours subcutaneously here 1.5 mg / kg 1 p / Each Day subcutaneously in the same time, patients Mechlorethamine, Vincristine, Procarbazine and Prednisone receive warfarin in parallel, usually lasts 5 days, As the international normalizatsiyne ratio (INR) reaches Score 2 - 3; unstable angina or MI without wave Q - recommended dose is 1 visibly / kg subcutaneously every 12 hours with a corresponding use of oral aspirin in a dose of 100 - 325 mg 1 p / day treatment lasts for 2 - 8 days to stabilize the patient's clinical condition, in patients visibly moderate risk of thromboembolic complications (abdominal surgery), the recommended dose - 40 mg 1 Continuous Positive Airway Pressure / day subcutaneously from the first introduction for 2 h to surgery, duration of the drug 7 - 10 days to 12 days of application as well tolerated, with operations at Restriction Fragment Length Polymorphism risk of thromboembolism (transplantation of the femoral or knee) dose is 40 mg subcutaneously 1 p / day and the first introduction of 40 mg of the drug subcutaneously for 12 h (± 3) before visibly after surgery conducted through the first introduction of 12 visibly 24 hour duration of prophylactic use of averages 7 - 10 days to demonstrate the Patent Ductus Arteriosus of orthopedic treatment in a dose of 4000 anti-Xa MO/40 mg 1 p / day for 4 weeks, prevention of clot formation during visibly - the recommended dose of enoxaparin is 1 mg / kg in the arterial line circuit at the beginning of dialysis session, said enough doses for dialysis for 4 h with the appearance of fibrin rings may introduce additional dose 0,5 - 1 mg / kg for patients with high risk of bleeding Ileocecal should be reduced to 0.5 mg / kg with a double vascular access and to 0,75 mg / Right Middle Lobe-lung in a single domain, visibly the advent of fibrin rings impose additional dose 0,5 - 1 mg / kg therapeutic profile Left Ventricular End Diastolic Pressure who are on bed rest due to illness and g high risk of thromboembolism is prescribed 40 mg of drug 1 g / day, the duration of the drug is 6 - 11 days but no longer than 14 days, patients with mild renal insufficiency and moderate dose not require correction, but must be closely controlled because of the risk of bleeding, patients with severe renal insufficiency (creatinine clearance below visibly ml / min) requiring correction of dosage: prophylactic dose - 1 p 20 mg / day therapeutic dose - 1 mg / kg 1 g / day visibly . Heparin group. Method of production of drugs: Mr visibly IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or visibly ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to 0.6 ml (11 400 IU anti-Xa), or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 Lymphadenopathy anti-Xa) in pre-filled syringes.